Plain-English translation of NCT06455319 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Type 1 Diabetes research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This research study is testing whether , a medication that modulates the immune system, can help preserve your body's ability to produce insulin when given shortly after a type 1 diabetes diagnosis. Researchers will compare people who receive the medication to those who receive a placebo (inactive treatment) to see if ATG slows down the loss of insulin-producing cells. A second part of the study will also explore whether adding another medication called verapamil provides additional benefit.
Type 1 diabetes happens when the immune system mistakenly attacks insulin-producing cells in the pancreas. This trial exists because there is currently no approved treatment that can stop or slow this damage in newly diagnosed patients, and researchers believe that an immune-modulating medication given early might help preserve the pancreas's remaining ability to make insulin.
You likely qualify if…
You likely don't qualify if…
In the first year, you will receive either the study medication or a placebo as an intravenous infusion over two days, then be closely monitored with blood tests and meal tolerance tests to measure how much insulin your pancreas is still making. After that year ends, you will enter a second year where you may also receive an oral medication (verapamil) while continuing to have regular clinic visits and blood work to check your diabetes control and immune response.
AI-generated summary from trial data · Jun 25, 2026 · Not medical advice
United States